Yasuo Hamamoto

Prof. Yasuo Hamamoto

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
TKToshihiro Kudo
Toshihiro Kudo
YHYasuo Hamamoto
Yasuo Hamamoto
KKKen Kato
Ken Kato
TUTakashi Ura
Takashi Ura
TKTakashi Kojima
Takashi Kojima
YKYuko Kitagawa
Yuko Kitagawa

1 November 2020 in Cell
Verified
Journal Article
Closed access
KKKenta Kawasaki
Kenta Kawasaki
KTKohta Toshimitsu
Kohta Toshimitsu
MMMami Matano
Mami Matano
MFMasashi Fujita
Masashi Fujita
MFMasayuki Fujii
Masayuki Fujii
TSToshiro Sato
Toshiro Sato

16 March 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MOMorihito Okada
Morihito Okada
KKKen Kato
Ken Kato
BCByoung Chul Cho
Byoung Chul Cho
MTMasanobu Takahashi
Masanobu Takahashi
CLChen-Yuan Lin
Chen-Yuan Lin
YKYuko Kitagawa
Yuko Kitagawa
Purpose: Limited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up data from our study of nivolumab versus chemotherapy (paclitaxel or docetaxel) in patients with previously treated ESCC. Patients and Methods: ATTRACTION-3 was a randomized, multicenter, open-label, phase III trial. Overall survival (OS), time from randomization to death from any cause, was the primary endpoint. An exploratory subanalysis assessed OS according to the best overall response (BOR) with and without landmark at 4 months. Results: Of the enrolled patients, 210 received nivolumab and 209 received chemotherapy. With a minimum follow-up of 36.0 months, OS was longer in the nivolumab versus the chemotherapy group (median, 10.9 vs. 8.5 months; HR, 0.79; P = 0.0264), with 3-year OS rates of 15.3% and 8.7%, respectively. The median OS was longer with nivolumab versus chemotherapy irrespective of the BOR (complete response/partial response: 19.9 vs. 15.4 months; stable disease: 17.4 vs. 8.8 months; and progressive disease: 7.6 vs. 4.2 months). Grade 3 or higher treatment-related adverse events were reported in 40 patients (19.1%) in the nivolumab group and 133 patients (63.9%) in the chemotherapy group. Conclusions: Nivolumab as second-line therapy demonstrated clinically meaningful long-term improvement in OS compared with chemotherapy in previously treated patients with advanced ESCC. The OS was consistently improved in the nivolumab group compared with the chemotherapy group regardless of BOR. Nivolumab was well tolerated over the 3-year follow-up. See related commentary by Yoon et al., p. 3173

21 April 2021 in Future Oncology
Verified
Journal Article
Open access
KSKeitaro Shimozaki
Keitaro Shimozaki
YSYasutaka Sukawa
Yasutaka Sukawa
YSYasunori Sato
Yasunori Sato
SHSara Horie
Sara Horie
ACAkihiko Chida
Akihiko Chida
TKTakanori Kanai
Takanori Kanai
The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patie...

30 April 2022 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YHYasuo Hamamoto
Yasuo Hamamoto
KMKentaro Murakami
Kentaro Murakami
KKKen Kato
Ken Kato
YKYuko Kitagawa
Yuko Kitagawa
This review focuses on the treatment about elderly esophageal cancer to clarify the current situation regarding our clinical question. Although there are several reviews about elderly esophageal cancer treatment, there are fundamental differences between Japan and the rest of the world. Two main differences are raised: histological differences and treatment strategies for resectable patients. We overview each status according to following clinical questions. First, there are no established evaluation criteria for frail. Second, selection criteria for surgery or non-surgery are not established. Third, few specific treatments for elderly patients (EPs) are investigated. In conclusion, there are many reports about treatment of esophageal squamous cell carcinoma for EPs, although treatment strategy is still controversial. We have to consider well-designed prospective trial to confirm specific treatment strategy according to each stage.

9 May 2009 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YHYasuo Hamamoto
Yasuo Hamamoto
MKMasaaki Kataoka
Masaaki Kataoka
TSTakatoshi Senba
Takatoshi Senba
KUKotaro Uwatsu
Kotaro Uwatsu
YSYoshifumi Sugawara
Yoshifumi Sugawara
SOShogo Oda
Shogo Oda
To find vertebral metastases with high risk of symptomatic malignant spinal cord compression (MSCC), features of vertebral metastases caused motor deficits of the lower extremities were examined. From 2004 through 2006, 78 patients with metastases of the thoracic and/or the cervical spine were treated with radiation therapy (RT). Of these, 86 irradiated lesions in 73 patients were evaluable by magnetic resonance imaging and/or computed tomography at the initiation of RT and were reviewed retrospectively in this study. Twenty-eight patients (38%) had motor deficits at the initiation of RT. Assessed factors were age, sex, primary disease (lung, breast, digestive system and other cancer), lamina involvement, main level of tumor location and vertebral-body involvement. Incidence of motor deficits at the initiation of RT was 55% for lesions with lamina involvement and 5% for lesions without lamina involvement (P < 0.0001). Incidence of motor deficits was 15% for lesions located mainly in the cervical spine and/or the upper thoracic spine (Th1–4), 54% for lesions located mainly in the middle thoracic spine (MTS) (Th5–8) and 30% for lesions located mainly in the lower thoracic spine (Th9–12) (P = 0.0095). Age, sex, primary disease and vertebral-body involvement were not statistically significant factors for incidence of motor deficits due to MSCC (P > 0.9999, P = 0.7798, P = 0.1702 and P = 0.366, respectively). Vertebral metastases with lamina involvement tended to cause symptomatic MSCC. Latent development of MSCC occurred more frequently in the MTS compared with other levels of the thoracic and the cervical spine.